Shiral Gangadin

Dr. Shiral Gangadin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
ISIris E Sommer
Iris E Sommer
BBBodyl A Brand
Bodyl A Brand
SGShiral Gangadin
Shiral Gangadin
ATAntti Tanskanen
Antti Tanskanen
JTJari Tiihonen
Jari Tiihonen
HTHeidi Taipale
Heidi Taipale
Throughout the life stages of women with schizophrenia-spectrum disorders (SSD), lower estrogen levels are associated with more severe disease course. At perimenopause in the mid-forties, estrogen levels decline to remain persistently low after menopause. This period is hypothesized to increase relapse risk and reduce antipsychotic effectiveness in preventing relapse. The cohort of persons with schizophrenia/schizoaffective disorder was identified from Finnish nationwide registers (N = 61 889) and stratified by sex and age <45 vs. ≥45 years. Hospitalizations for psychosis were defined per 5-year age group during the follow-up 1996–2017. Risk of psychosis hospitalization (Adjusted Hazard Ratio, aHR) was assessed using within-individual design, by comparing antipsychotic monotherapy use to nonuse periods in the same individuals for seven dose categories in defined daily doses (DDDs/day). Starting at age 45–50, women were consistently more often hospitalized for psychosis than their male peers. Women ≥45 had significantly higher aHRs than women 0.6 DDDs/day, and than men at >1.1 DDDs/day. This female-specific age-dependent decrease in effectiveness was present for clozapine doses >0.6 DDDs/day, olanzapine doses >1.4 DDDs/day, and for specific doses of quetiapine (0.9–1.1 DDDs/day) and risperidone (0.6–0.9 DDDs/day). While younger women have a lower risk of relapse and generally need a lower antipsychotic dose to prevent rehospitalization than men, antipsychotic effectiveness declines in women after the age of 45. Starting in mid-forties, older women with SSD should be regarded as a vulnerable group that deserve special attention.

28 October 2025 in Schizophrenia Bulletin
Verified
Journal Article
Open access
FBFranciska de Beer
Franciska de Beer
IHIris M H Hamers
Iris M H Hamers
MPMichalina Prycka
Michalina Prycka
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
SGShiral Gangadin
Shiral Gangadin
ISIris E C Sommer
Iris E C Sommer
Background and Hypothesis: During menopause, estrogen levels change dramatically, which may decrease clozapine blood concentrations in women via estrogen’s inhibitory effect on CYP1A2 activity. This reduction could contribute to increased relapse rates seen in older women with psychotic disorders. Study Design: Clozapine blood concentration data were retrieved from the University Medical Center Groningen, the Netherlands. A total of 982 patients (720 men, 262 women), aged 40-60, with 17 104 measurements, were included for analyses. Latent class growth analysis (LCGA) assessed clozapine trajectories by sex, while linear mixed-effects models (LMEM) assessed sex differences between trajectory classes. Study Results: The optimal LCGA model (7-quantile splines) identified 3 clusters. Most women (n = 157, 60%) showed a decline in clozapine levels from 520 to 400 μg/L between the ages of 40-60. In contrast, most men (n = 392, 54%) had stable levels (mean 460 μg/L). Two other trajectories appeared in both sexes: a mild increase starting at age 45 (men: n = 272, 38%; women: n = 97, 37%) and a marked increase from 40 to 60 (men: n = 56, ~8%; women: n = 8, ~3%). LMEM showed significantly higher levels in women than men with stable trajectories (estimate = 177.03, t = 2.62, P < .01). A significant age-by-sex interaction (estimate = −0.067, t = −2.63, P < .01) suggested these differences varied over time. Conclusions: Sex-specific longitudinal trajectories of clozapine concentrations showed declines in 60% of women aged 40-60, while most men remained stable. As decreasing blood levels could increase relapse vulnerability, monitoring clinical efficacy and side effects is warranted during menopause.

8 September 2025 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
FBFranciska de Beer
Franciska de Beer
Erik de VriesErik de Vries
Erik de Vries
BWBen Wijnen
Ben Wijnen
MBMarieke J.H. Begemann
Marieke J.H. Begemann
NBNico van Beveren
Nico van Beveren
ISIris E.C. Sommer
Iris E.C. Sommer
Background: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D2 receptor (D2R) antagonist and partial agonist antipsychotics on striatal dopamine D2/3R availability in FEP patients. Methods: Remitted FEP patients underwent two [11C]raclopride PET scans to measure striatal D2/3R availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6–8 weeks (n = 8 antagonist users, n = 5 partial agonist users). Fifteen matched healthy controls were scanned once. Psychotic relapse was monitored up to 12 months after discontinuation. Results: One week after discontinuation, D2R antagonist discontinuers showed higher striatal binding potential (BPND) than partial D2R agonist discontinuers (p < 0.001, CI = 0.749 to 1.681) and controls (p = 0.045, CI = 0.008 to 0.708), while partial agonist discontinuers had significantly lower BPND than controls (p = 0.001, CI = -1.326 to -0.386). 6-8 weeks after discontinuation, former antagonist users showed similar BPND to controls (p > 0.25), whereas former partial agonist users had higher BPND than controls (p = 0.027, CI = 0.069 to 1.085). Participants who discontinued antagonists relapsed more often (81%) than those who discontinued partial agonists (17%)(χ2 = 5.32, p = 0.021). Conclusions: Discontinuation of partial D2R agonists may affect D2/3R availability differently than discontinuation of antagonists, which might explain the greater relapse risk after tapering antagonists than partial agonist antipsychotics.

13 August 2025 in Schizophrenia Bulletin
Verified
Journal Article
Open access
SCStijn Crutzen
Stijn Crutzen
SGShiral Gangadin
Shiral Gangadin
KHKen Ho Hua
Ken Ho Hua
EVEllen Visser
Ellen Visser
FJFrederike Jörg
Frederike Jörg
SCStynke Castelein
Stynke Castelein
Background: Antipsychotics are used to manage symptoms and reduce the risk of relapse. However, the antipsychotic side effects are associated with a lower quality of life and are seen as major barriers to achieving societal recovery by antipsychotic users. In this study, we investigate the association of side effects, antipsychotic dose, and antipsychotic polypharmacy with societal recovery and happiness. Study Design: Data were used from a large, naturalistic, longitudinal cohort of people using an antipsychotic in long-term care (Pharmacotherapy Monitoring and Outcome Survey [PHAMOUS], 2013-2021). The association between subjective antipsychotic side-effect burden (measured with the Subjective Response to Antipsychotics questionnaire), antipsychotic dose, and antipsychotic polypharmacy with societal recovery and happiness was investigated using mixed-effect linear regression models. In an exploratory analysis, the associations between individual side effects with societal recovery and happiness were assessed. Study Results: Data from 5971 observations nested in 2490 participants were used. The subjective antipsychotic side-effect burden, total antipsychotic dose, and antipsychotic polypharmacy were significantly negatively associated with societal recovery. Subjective antipsychotic side-effect burden and total antipsychotic dose were significantly negatively associated with happiness, but antipsychotic polypharmacy was not. Cognitive, mood, and physical anticholinergic side effects were most strongly negatively associated with societal recovery. Mood-, sedation-, cognitive-, and sexual-related side effects were most strongly negatively associated with happiness. Conclusions: These results show that side effects and a higher dose of antipsychotic medication are negatively associated with societal functioning and happiness. Future research should focus on whether dose reduction is beneficial for societal recovery and happiness in the long-term.

27 December 2022 in Schizophrenia Research
Verified
Journal Article
Open access
SGShiral Gangadin
Shiral Gangadin
RMRené C.W. Mandl
René C.W. Mandl
LWLot D. de Witte
Lot D. de Witte
NHNeeltje E.M. van Haren
Neeltje E.M. van Haren
MSMaya J.L. Schutte
Maya J.L. Schutte
ISIris E.C. Sommer
Iris E.C. Sommer
Various lines of research suggest immune dysregulation as a potential therapeutic target for negative and cognitive symptoms in schizophrenia spectrum disorders (SSD). Immune dysregulation would lead to higher extracellular free-water (EFW) in cerebral white matter (WM), which may partially underlie the frequently reported lower fractional anisotropy (FA) in SSD. We aim to investigate differences in EFW concentrations - a presumed proxy for neuro-inflammation - between early-phase SSD patients (n = 55) and healthy controls (HC; n = 37), and to explore immunological and cognitive correlates. To increase specificity for EFW, we study several complementary magnetic resonance imaging contrasts that are sensitive to EFW. FA, mean diffusivity (MD), magnetization transfer ratio (MTR), myelin water fraction (MWF) and quantitative T1 and T2 were calculated from diffusion-weighted imaging (DWI), magnetization transfer imaging (MTI) and multicomponent driven equilibrium single-pulse observation of T1/T2 (mcDESPOT). For each measure, WM skeletons were constructed with tract-based spatial statistics. Multivariate SSD-HC comparisons with WM skeletons and their average values (i.e. global WM) were not statistically significant. In voxel-wise analyses, FA was significantly lower in SSD in the genu of the corpus callosum and in the left superior longitudinal fasciculus (p < 0.04). Global WM measures did not correlate with immunological markers (i.e. IL1-RA, IL-6, IL-8, IL-10 and CRP) or cognition in HC and SSD after corrections for multiple comparisons. We confirmed lower FA in early-phase SSD patients. However, nonFA measures did not provide additional evidence for immune dysregulation or for higher EFW as the primary mechanism underlying the reported lower FA values in SSD.

2 January 2026 in Psychological Medicine
Verified
Journal Article
Open access
POPriscilla P. Oomen
Priscilla P. Oomen
SGShiral Gangadin
Shiral Gangadin
LHLieuwe de Haan
Lieuwe de Haan
FBFranciska de Beer
Franciska de Beer
OBOda E. Beune
Oda E. Beune
ISIris E.C. Sommer
Iris E.C. Sommer
Background: Evidence regarding the effects of antipsychotic medication on cognitive functioning after a first-episode psychosis (FEP) remains inconclusive. This study examined whether dopamine D 2 receptor occupancy, affinity, and antipsychotic dose are related to cognitive functioning in people in remission from FEP. Methods: 278 remitted FEP participants from the HAMLETT-trial were included. Cognitive functioning was assessed with the Brief Assessment of Cognition in Schizophrenia, 3–6 months after remission. D 2 receptor occupancy was estimated based on antipsychotic type and dose. Antipsychotics were categorized into partial agonists, or antagonists with high or low D 2 receptor affinity. Linear regression analyses were performed with inverse probability of treatment weighting to control for differences in characteristics between groups. Results: D 2 receptor occupancy was negatively related to global cognition ( β = −0.18), verbal fluency ( β = −0.22), and attention and processing speed ( β = −0.17, all p < 0.003). The interaction between daily dose and D 2 receptor affinity category was significant for global cognition ( p = 0.0046) and working memory ( p = 0.0019), but not for verbal fluency after correction for multiple testing ( p = 0.029). Interactions showed that higher daily dose was related to lower cognitive functioning, with significantly stronger negative effects in high-affinity antagonists compared to other antipsychotics. Conclusions: The current findings underscore the importance of antipsychotic D 2 receptor occupancy and affinity for cognitive functioning and suggest better cognitive functioning in users of partial agonists and low D 2 receptor affinity antipsychotics. This can be important when selecting antipsychotics for individuals with FEP.